Two 2024 launches ended a decade of inhaler-only competition — but each treats a different slice of the triple-therapy failure population
Through 2023 the US COPD maintenance market was a two-horse inhaler race: GSK's Trelegy Ellipta and AstraZeneca's Breztri Aerosphere, both single-inhaler ICS/LAMA/LABA triples competing on exacerbation and mortality data (IMPACT and ETHOS). The strategic question was device, dosing, and formulary tier — not mechanism. That question is now obsolete for the patients who still exacerbate on triple therapy.
In mid-2024 the FDA approved ensifentrine (Ohtuvayre), the first novel inhaled mechanism in COPD in more than twenty years, and dupilumab (Dupixent), the first biologic ever approved in COPD. They do not compete head-to-head: ensifentrine is a non-steroidal add-on usable at any step, while dupilumab is gated to the roughly type-2/eosinophilic endotype on maximal triple therapy. The commercial contest is now about which failure phenotype a payer will pay to treat, and with what.
Six regimens define the US COPD maintenance market: two incumbent triples, two 2024 first-in-class add-ons, one oral PDE4, one dual-bronchodilator base
| Brand (INN) | Class / mechanism | Company | US approval | Key trial — result | Positioning |
|---|---|---|---|---|---|
| Trelegy Ellipta (fluticasone furoate / umeclidinium / vilanterol) | ICS/LAMA/LABA single-inhaler triple, once-daily | GSK | 2017 (COPD) | IMPACT — 25% fewer mod/severe exacerbations vs LAMA/LABA (RR 0.75); PMID 29668352 | Once-daily triple anchor; broad exacerbation-history use, market leader |
| Breztri Aerosphere (budesonide / glycopyrrolate / formoterol) | ICS/LAMA/LABA triple (metered-dose), twice-daily | AstraZeneca | 2020 | ETHOS — all-cause mortality signal + CV/cardiopulmonary benefit vs LAMA/LABA; PMID 39213002 | Twice-daily MDI triple; mortality and cardiovascular-safety narrative |
| Dupixent (dupilumab) | IL-4R-alpha monoclonal antibody, anti-type-2 biologic (add-on, SC) | Sanofi / Regeneron | 2024 (Sept) | BOREAS + NOTUS — 31% fewer exacerbations (IRR 0.687); PMIDs 37272521, 38767614, 39900091 | First biologic in COPD; add-on for eosinophils >=300 on triple therapy |
| Ohtuvayre (ensifentrine) | Inhaled dual PDE3/PDE4 inhibitor, non-steroidal (nebulized) | Verona Pharma (acquired by Merck, 2025) | 2024 (June) | ENHANCE-1/2 — 41% fewer exacerbations pooled (RR 0.59) + FEV1 gain; PMIDs 37364283, 39197510 | First novel inhaled mechanism in COPD in 20+ years; add at any step, phenotype-agnostic |
| Daliresp / roflumilast (generic) | Oral PDE4 inhibitor | Generic (orig. AstraZeneca) | 2011 | REACT — ~14% fewer exacerbations added to ICS/LABA; PMID 25684586 | Oral add-on for severe chronic-bronchitis exacerbators; tolerability-limited uptake |
| LAMA/LABA duals (e.g., Anoro, Stiolto) | Dual long-acting bronchodilator, no steroid | GSK / Boehringer Ingelheim | 2013-2015 | Foundation maintenance; ICS/add-on layered by eosinophils + exacerbation history | Step-up base of the pathway; the denominator every add-on sits on top of |
Sources: IMPACT: NEJM 2018, PMID 29668352, doi:10.1056/NEJMoa1713901. ETHOS CV/mortality analysis: AJRCCM 2025, PMID 39213002, doi:10.1164/rccm.202312-2311OC. BOREAS: NEJM 2023, PMID 37272521. NOTUS: NEJM 2024, PMID 38767614. Pooled dupilumab: Lancet Respir Med 2025, PMID 39900091, doi:10.1016/S2213-2600(24)00409-0. ENHANCE trials: AJRCCM 2023, PMID 37364283; pooled exacerbation analysis Chest 2024, PMID 39197510, doi:10.1016/j.chest.2024.07.168. REACT: Lancet 2015, PMID 25684586, doi:10.1016/S0140-6736(14)62410-7. Approvals and sponsors: FDA Drugs@FDA (NDA209482 Trelegy; NDA212122 Breztri; NDA217389 Ohtuvayre; Dupixent BLA label). All PMIDs verified live via PubMed.
What this brief answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- Endotype segmentation: eosinophil-gated (dupilumab, eos >=300) vs mechanism-agnostic (ensifentrine), with the triple-therapy-failure denominator each competes for
Delivers
- A sequencing map showing where the two 2024 entrants overlap, where they are additive, and where roflumilast still holds the oral-add-on niche
Delivers
- A read on GSK/AstraZeneca positioning, mortality and CV narratives (ETHOS) vs the add-on tier, and the reformulation/device levers left to them
Custom brief delivered in 72 hours.
Commission This BriefWhat's inside
- How Trelegy Ellipta and Breztri Aerosphere's single-inhaler triple competition (IMPACT, ETHOS) has been overtaken by a biology-defined add-on tier
- Why ensifentrine and dupilumab, both approved in 2024, target patients who still exacerbate despite maximal triple therapy
- Full drug profiles spanning Trelegy, Breztri, Dupixent, Ohtuvayre, generic roflumilast, and LAMA/LABA duals
- Why dupilumab (2024) is the first-ever COPD biologic and ensifentrine the first novel inhaled mechanism in over twenty years
- The pivotal-trial exacerbation reductions: 25% for Trelegy (IMPACT), 41% for ensifentrine (pooled ENHANCE), and 31% for dupilumab (pooled BOREAS+NOTUS)
- How ETHOS's mortality and cardiopulmonary-benefit signal differentiates Breztri from the IMPACT-based triple benchmark
- Why dupilumab is gated to the roughly type-2/eosinophilic endotype (eos >=300) on maximal triple therapy, while ensifentrine is phenotype-agnostic
- How the eosinophil-count threshold determines which failure phenotype a payer will pay to treat, and with what
- The pipeline landscape building on the eosinophil-gated and mechanism-agnostic precedents set by dupilumab and ensifentrine
- Where roflumilast's oral add-on niche still holds against the two 2024 entrants
- GSK and AstraZeneca's positioning options, including ETHOS's mortality and CV narratives, against the new add-on tier
- The reformulation and device levers left to the incumbent triples as biology reshapes the conversation
Included with every brief
How AXLRx builds this brief
Prepared by MoatRx analysts.
Every AXLRx brief is built from primary regulatory sources (FDA, ClinicalTrials.gov), peer-reviewed literature, and live payer policy documentation — not secondary summaries. No secondary summaries, market research reports, or unverified estimates are used. Findings are independently verified before inclusion.
US COPD Competitive Intelligence sources: FDA Drugs@FDA (approvals and labels), primary trial publications, ClinicalTrials.gov, and live payer/HTA policy documentation.
- Every trial PMID verified live via PubMed this run; returned title matches the cited trial in each case.
- FDA approvals confirmed via Drugs@FDA: Ohtuvayre/ensifentrine approved 26 Jun 2024 (NDA217389, now sponsored by MSD after Merck's 2025 acquisition of Verona Pharma); Breztri NDA212122 (AstraZeneca); Trelegy NDA209482 (GSK).
- Dupixent COPD indication confirmed on the current FDA label (IL-4-receptor-alpha antagonist, Sanofi-Aventis); COPD add-on approval Sept 2024.
Frequently asked questions
Commission this brief
AXLRx delivers US COPD competitive intelligence built for pharma and biotech commercial, access, and medical affairs teams. Custom brief in 72 hours.
Use the intake form to specify your indication, geography, and commercial question.
AXLRx analyst confirms scope, comparators, and delivery format.
Research-verified brief in 72 hours with optional analyst readout.